$HAIXI PHARMA(02637)$ view ord

cartoon2000

2025-10-16

$HAIXI PHARMA(02637)$ view order details.@Trade Feed Decoder

02637

10-16 16:41

HKHAIXI PHARMA

Side	Price \| Filled	Realized P&L
Buy Open	109.61 500	-- Closed

HAIXI PHARMA

Trade Feed: Who is your favorite trader?

Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the "hidden gem traders" that you've discovered!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Trade Feed Decoder
2025-10-16
Trade Feed Decoder
Analysis of HAIXI PHARMA (02637) trade: The -1.37% realized loss suggests potential challenges in timing or entry-level selection. Pharmaceutical stocks like HAIXI often face sector-specific volatility due to regulatory news or clinical trial outcomes, which could have influenced this short-term outcome. The trade’s structure implies a tactical, possibly momentum-driven approach, though the quick exit indicates disciplined risk management to limit downside. Investors might reflect on whether fundamental factors (e.g., earnings, pipeline updates) aligned with the entry rationale. For similar trades, balancing sector sensitivity with technical indicators could improve decision-making. The moderate loss percentage highlights the importance of position sizing in volatile sectors. Further scrutiny of liquidity and intraday patterns for Hong Kong-listed stocks may add contextual value.

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":489802636501560,"tweetId":"489802636501560","gmtCreate":1760604122195,"gmtModify":1761014682291,"author":{"id":4150717321751252,"idStr":"4150717321751252","authorId":4150717321751252,"authorIdStr":"4150717321751252","name":"cartoon2000","avatar":"https://community-static.tradeup.com/news/b6cde0aa46f675b08b1fc7675f64daee","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":3480,"starInvestorFlag":true,"fullDisclosureFlag":true,"starInvestorFollowerNum":2418,"starInvestorOrderShareNum":952,"userFollowInvestorFlag":false,"orderNotificationFlag":false,"ror":505.05,"showRor":true,"investmentPhilosophy":"超進取投資","winRationPercentage":52.795031,"tradeVolumeEst":0},"themes":[{"themeId":"4e1ab37448a24dd39b7882426fc6fd27","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"Trade Feed: Who is your favorite trader?","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":4e1ab37448a24dd39b7882426fc6fd27}&rnconfig={\"headerBarHidden\": true}","description":"Come to the Trade Feed Topic to find more trading opportunities! Also, please feel free to recommend and introduce fellow Tigers to the \"hidden gem traders\" that you've discovered!","image":"https://community-static.tradeup.com/news/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://ttm.financial/S/02637\">$HAIXI PHARMA(02637)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/02637\">$HAIXI PHARMA(02637)$&nbsp;</a>view order details.<a href=\"https://ttm.financial/U/10000000000011061\">@Trade Feed Decoder</a></body></html>","text":"$HAIXI PHARMA(02637)$ view order details.@Trade Feed Decoder","highlighted":1,"essential":1,"paper":1,"likeSize":21,"commentSize":1,"repostSize":15,"favoriteSize":0,"link":"https://ttm.financial/post/489802636501560","repostId":0,"isVote":1,"tweetType":1,"viewCount":499,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02637"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4150717321751252","orderId":"40855764065079296","kind":"TRADE","symbol":"02637","secType":"STK","symbolHtmlTag":"<a href=\"https://ttm.financial/S/02637\">$HAIXI PHARMA(02637)$&nbsp;</a>","symbolHtmlTagHref":"https://ttm.financial/S/02637","symbolName":"HAIXI PHARMA","market":"HK","action":"BUY","currency":"HKD","symbolLogo":"","showFilledQuantity":true,"nameCN":"HAIXI PHARMA","orderType":"LMT","filledQuantityFinal":500,"avgFillPrice":109.61,"createTime":1760604081,"filledQuantity":"500","filledQuantityScale":"0","openFlag":true,"side":"DEBIT","contractMajorDescription":"HAIXI PHARMA","contractExtraDescription":"02637","legs":[],"completedFlag":true,"orderPnl":{"openRealizedPnlPercent":-0.0994},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖","未分享订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":34,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":489831742038872,"commentId":"489831742038872","gmtCreate":1760611235635,"gmtModify":1760611240426,"authorId":10000000000011060,"author":{"id":10000000000011060,"idStr":"10000000000011061","authorId":10000000000011060,"name":"Trade Feed Decoder","avatar":"https://community-static.tradeup.com/news/4dc8fec78bad5acffbf563bdbc6bc8ed","vip":4,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":489802636501560,"objectIdStr":"489802636501560","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Analysis of HAIXI PHARMA (02637) trade: The -1.37% realized loss suggests potential challenges in timing or entry-level selection. Pharmaceutical stocks like HAIXI often face sector-specific volatility due to regulatory news or clinical trial outcomes, which could have influenced this short-term outcome. The trade’s structure implies a tactical, possibly momentum-driven approach, though the quick exit indicates disciplined risk management to limit downside. Investors might reflect on whether fundamental factors (e.g., earnings, pipeline updates) aligned with the entry rationale. For similar trades, balancing sector sensitivity with technical indicators could improve decision-making. The moderate loss percentage highlights the importance of position sizing in volatile sectors. Further scrutiny of liquidity and intraday patterns for Hong Kong-listed stocks may add contextual value.","text":"Analysis of HAIXI PHARMA (02637) trade: The -1.37% realized loss suggests potential challenges in timing or entry-level selection. Pharmaceutical stocks like HAIXI often face sector-specific volatility due to regulatory news or clinical trial outcomes, which could have influenced this short-term outcome. The trade’s structure implies a tactical, possibly momentum-driven approach, though the quick exit indicates disciplined risk management to limit downside. Investors might reflect on whether fundamental factors (e.g., earnings, pipeline updates) aligned with the entry rationale. For similar trades, balancing sector sensitivity with technical indicators could improve decision-making. The moderate loss percentage highlights the importance of position sizing in volatile sectors. Further scrutiny of liquidity and intraday patterns for Hong Kong-listed stocks may add contextual value.","html":"Analysis of HAIXI PHARMA (02637) trade: The -1.37% realized loss suggests potential challenges in timing or entry-level selection. Pharmaceutical stocks like HAIXI often face sector-specific volatility due to regulatory news or clinical trial outcomes, which could have influenced this short-term outcome. The trade’s structure implies a tactical, possibly momentum-driven approach, though the quick exit indicates disciplined risk management to limit downside. Investors might reflect on whether fundamental factors (e.g., earnings, pipeline updates) aligned with the entry rationale. For similar trades, balancing sector sensitivity with technical indicators could improve decision-making. The moderate loss percentage highlights the importance of position sizing in volatile sectors. Further scrutiny of liquidity and intraday patterns for Hong Kong-listed stocks may add contextual value.","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerFlag":true,"disclaimerType":1,"specialCommentTag":"AI_ANALYSE"}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/489802636501560"}